In Brief: Diphenhydramine
This article was originally published in The Tan Sheet
Executive Summary
Diphenhydramine: Warner-Lambert urges FDA in May 9 comments to allow OTC marketing of diphenhydramine hydrochloride as a single ingredient with labeling for both antihistamine and antitussive use beginning June 5. The agency proposed in a Feb. 23 amendment to the cough/cold combination TFM to allow single-ingredient products with both indications. However, the agency has not announced whether marketing could begin prior to publication of the cough/cold combination final monograph. P&G submitted a similar request on May 9 ("The Tan Sheet" May 22, p. 8)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning